Retatrutide 20mg

Retatrutide 20mg — Triple GLP-1, GIP, and Glucagon Receptor Agonist Research Peptide

Retatrutide is a synthetic 39-amino-acid peptide engineered as a triple agonist at GLP-1, GIP, and glucagon receptors. Representing the most advanced multi-receptor incretin research compound currently available, Retatrutide builds on the dual-agonist concept by adding glucagon receptor activation to GLP-1/GIP signaling. Published preclinical and clinical research has documented unprecedented metabolic effects, making Retatrutide one of the most discussed compounds in the modern weight management peptides research category.

Triple Receptor Pharmacology

Retatrutide’s triple agonist activity provides a research profile not achievable with single- or dual-receptor compounds. The peptide simultaneously activates GLP-1 receptors (insulin secretion, gastric emptying, appetite regulation), GIP receptors (additional insulinotropic activity, adipose effects), and glucagon receptors, which contribute energy expenditure effects through hepatic and thermogenic mechanisms. The integrated signaling produces a multi-pathway metabolic profile.

Glucagon Receptor Contribution

The addition of glucagon receptor activation distinguishes Retatrutide from prior incretin-only compounds. Glucagon signaling increases energy expenditure through hepatic effects on glucose and lipid metabolism, increases in metabolic rate, and effects on adipose tissue browning. Combined with GLP-1-mediated appetite suppression and gastric emptying, the energy expenditure increase from glucagon agonism creates a research compound that affects both sides of the energy balance equation.

Body Composition Research

Research has documented remarkable effects of Retatrutide on body composition in animal models. Studies have shown substantial reductions in body weight, predominantly through adipose mass loss, with relative preservation of lean tissue. The magnitude of these effects in preclinical and early clinical studies exceeds that observed with mono- or dual-incretin compounds in matched comparisons.

Dose-Response Research at 20mg

The 20mg format supports moderate-to-high concentration research designs and is a popular choice for investigators running structured dose-response studies. The vial size sits between smaller research-scale vials and the larger 40mg/50mg presentations used for extended or chronic experimental protocols.

Glycemic and Metabolic Research

Despite glucagon agonism’s classical association with elevated glucose, research has documented favorable glycemic effects of Retatrutide in animal models. The combined effects of GLP-1, GIP, and glucagon agonism produce net improvements in glucose homeostasis, insulin sensitivity, and metabolic biomarkers. Studies have also documented improvements in lipid parameters and hepatic fat content in research models.

Hepatic and Cardiovascular Research

Retatrutide has been studied for hepatic effects given glucagon signaling’s central role in liver biology, with documented reductions in hepatic fat content and improvements in liver biomarkers in animal models. Cardiovascular research has examined effects on blood pressure, lipid profiles, and inflammatory parameters relevant to cardiometabolic biology.

Comparison With Related Weight Management Peptides

Retatrutide is frequently compared against single agonist Semaglutide and dual agonist Tirzepatide, as well as non-incretin compounds like AOD 9604. Other Retatrutide sizes (10mg, 15mg, 40mg, 50mg) are available for dose-response research designs.

Quality, Storage, and Compliance

Each vial of Retatrutide 20mg is manufactured to 99%+ HPLC-verified purity and supplied as a sterile lyophilized powder. Store unreconstituted vials at -20°C; reconstituted material should be refrigerated at 2–8°C. This Retatrutide product is sold strictly for in-vitro laboratory research only — not for human consumption, diagnostic use, or any clinical application. Buyers must comply with all applicable provincial and federal regulations.